Global KRAS G12C Inhibitors 麻豆原创 Research Report 2024

Publication ID:

PB512240317

Publication Date:

December 12, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for KRAS G12C Inhibitors was valued at US$ 130 million in the year 2023 and is projected to reach a revised size of US$ 2599 million by 2030, growing at a CAGR of 47.0% during the forecast period.
KARC G12C inhibitors are targeted therapeutics for G12C mutation, a specific mutation in the KRAS gene. KRAS gene mutations are prevalent in a variety of cancers, particularly in non-small cell lung cancer (NSCLC), where G12C mutations are a common driver. Its mechanism of action is to form covalent bonds with cysteine residues of the KRAS G12C mutant protein, locking KRAS in its inactive conformation and blocking its signaling, thereby inhibiting the proliferation of tumor cells. The development of this class of drugs offers a new therapeutic avenue for cancer patients carrying the KRAS G12C mutation, especially for those who are not sensitive to conventional chemotherapy.
North American market for KRAS G12C Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for KRAS G12C Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of KRAS G12C Inhibitors include Amgen, Innovent Biologics, Inc., Mirati Therapeutics, Genfleet Therapeutics (Shanghai), Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for KRAS G12C Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding KRAS G12C Inhibitors.
The KRAS G12C Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global KRAS G12C Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the KRAS G12C Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Amgen
Innovent Biologics, Inc.
Mirati Therapeutics
Genfleet Therapeutics (Shanghai), Inc.
by Type
Garsorasib
Fulzerasib
Adagrasib
Sotorasib
by Application
Hospital
Clinic
Others
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of KRAS G12C Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of KRAS G12C Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 KRAS G12C Inhibitors 麻豆原创 Overview
1.1 Product Definition
1.2 KRAS G12C Inhibitors by Type
1.2.1 Global KRAS G12C Inhibitors 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Garsorasib
1.2.3 Fulzerasib
1.2.4 Adagrasib
1.2.5 Sotorasib
1.3 KRAS G12C Inhibitors by Application
1.3.1 Global KRAS G12C Inhibitors 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global KRAS G12C Inhibitors 麻豆原创 Size Estimates and Forecasts
1.4.1 Global KRAS G12C Inhibitors Revenue 2019-2030
1.4.2 Global KRAS G12C Inhibitors Sales 2019-2030
1.4.3 Global KRAS G12C Inhibitors 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 KRAS G12C Inhibitors 麻豆原创 Competition by Manufacturers
2.1 Global KRAS G12C Inhibitors Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global KRAS G12C Inhibitors Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global KRAS G12C Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of KRAS G12C Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of KRAS G12C Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of KRAS G12C Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of KRAS G12C Inhibitors, Date of Enter into This Industry
2.8 Global KRAS G12C Inhibitors 麻豆原创 Competitive Situation and Trends
2.8.1 Global KRAS G12C Inhibitors 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest KRAS G12C Inhibitors Players 麻豆原创 Share by Revenue
2.8.3 Global KRAS G12C Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global KRAS G12C Inhibitors 麻豆原创 Scenario by Region
3.1 Global KRAS G12C Inhibitors 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global KRAS G12C Inhibitors Sales by Region: 2019-2030
3.2.1 Global KRAS G12C Inhibitors Sales by Region: 2019-2024
3.2.2 Global KRAS G12C Inhibitors Sales by Region: 2025-2030
3.3 Global KRAS G12C Inhibitors Revenue by Region: 2019-2030
3.3.1 Global KRAS G12C Inhibitors Revenue by Region: 2019-2024
3.3.2 Global KRAS G12C Inhibitors Revenue by Region: 2025-2030
3.4 North America KRAS G12C Inhibitors 麻豆原创 Facts & Figures by Country
3.4.1 North America KRAS G12C Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America KRAS G12C Inhibitors Sales by Country (2019-2030)
3.4.3 North America KRAS G12C Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe KRAS G12C Inhibitors 麻豆原创 Facts & Figures by Country
3.5.1 Europe KRAS G12C Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe KRAS G12C Inhibitors Sales by Country (2019-2030)
3.5.3 Europe KRAS G12C Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific KRAS G12C Inhibitors 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific KRAS G12C Inhibitors 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific KRAS G12C Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific KRAS G12C Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America KRAS G12C Inhibitors 麻豆原创 Facts & Figures by Country
3.7.1 Latin America KRAS G12C Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America KRAS G12C Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America KRAS G12C Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa KRAS G12C Inhibitors 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa KRAS G12C Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa KRAS G12C Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa KRAS G12C Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global KRAS G12C Inhibitors Sales by Type (2019-2030)
4.1.1 Global KRAS G12C Inhibitors Sales by Type (2019-2024)
4.1.2 Global KRAS G12C Inhibitors Sales by Type (2025-2030)
4.1.3 Global KRAS G12C Inhibitors Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global KRAS G12C Inhibitors Revenue by Type (2019-2030)
4.2.1 Global KRAS G12C Inhibitors Revenue by Type (2019-2024)
4.2.2 Global KRAS G12C Inhibitors Revenue by Type (2025-2030)
4.2.3 Global KRAS G12C Inhibitors Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global KRAS G12C Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global KRAS G12C Inhibitors Sales by Application (2019-2030)
5.1.1 Global KRAS G12C Inhibitors Sales by Application (2019-2024)
5.1.2 Global KRAS G12C Inhibitors Sales by Application (2025-2030)
5.1.3 Global KRAS G12C Inhibitors Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global KRAS G12C Inhibitors Revenue by Application (2019-2030)
5.2.1 Global KRAS G12C Inhibitors Revenue by Application (2019-2024)
5.2.2 Global KRAS G12C Inhibitors Revenue by Application (2025-2030)
5.2.3 Global KRAS G12C Inhibitors Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global KRAS G12C Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen KRAS G12C Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen KRAS G12C Inhibitors Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Innovent Biologics, Inc.
6.2.1 Innovent Biologics, Inc. Company Information
6.2.2 Innovent Biologics, Inc. Description and Business Overview
6.2.3 Innovent Biologics, Inc. KRAS G12C Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Innovent Biologics, Inc. KRAS G12C Inhibitors Product Portfolio
6.2.5 Innovent Biologics, Inc. Recent Developments/Updates
6.3 Mirati Therapeutics
6.3.1 Mirati Therapeutics Company Information
6.3.2 Mirati Therapeutics Description and Business Overview
6.3.3 Mirati Therapeutics KRAS G12C Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mirati Therapeutics KRAS G12C Inhibitors Product Portfolio
6.3.5 Mirati Therapeutics Recent Developments/Updates
6.4 Genfleet Therapeutics (Shanghai), Inc.
6.4.1 Genfleet Therapeutics (Shanghai), Inc. Company Information
6.4.2 Genfleet Therapeutics (Shanghai), Inc. Description and Business Overview
6.4.3 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Genfleet Therapeutics (Shanghai), Inc. KRAS G12C Inhibitors Product Portfolio
6.4.5 Genfleet Therapeutics (Shanghai), Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 KRAS G12C Inhibitors Industry Chain Analysis
7.2 KRAS G12C Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 KRAS G12C Inhibitors Production Mode & Process
7.4 KRAS G12C Inhibitors Sales and 麻豆原创ing
7.4.1 KRAS G12C Inhibitors Sales Channels
7.4.2 KRAS G12C Inhibitors Distributors
7.5 KRAS G12C Inhibitors Customers
8 KRAS G12C Inhibitors 麻豆原创 Dynamics
8.1 KRAS G12C Inhibitors Industry Trends
8.2 KRAS G12C Inhibitors 麻豆原创 Drivers
8.3 KRAS G12C Inhibitors 麻豆原创 Challenges
8.4 KRAS G12C Inhibitors 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Amgen
Innovent Biologics, Inc.
Mirati Therapeutics
Genfleet Therapeutics (Shanghai), Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.